EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The role of platelet P2Y 12 receptors in inflammation

William A E Parker iD, Robert F Storey iD

British Journal of Pharmacology · 2024-02 · 181 (4) · 515-531

DOI: 10.1111/bph.16256 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 02.11.2023. Verfasst von William A E Parker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation is a complex pathophysiological process underlying many clinical conditions. Platelets contribute to the thrombo‐inflammatory response. Platelet P2Y 12 receptors amplify platelet activation, potentiating platelet aggregation, degranulation and shape change. The contents of platelet alpha granules, in particular, act directly on leucocytes, including mediating platelet–leucocyte aggregation and activation via platelet P‐selectin. Much evidence for the role of platelet P2Y 12 receptors in inflammation comes from studies using antagonists of these receptors, such as the thienopyridines clopidogrel and prasugrel, and the cyclopentyltriazolopyrimidine ticagrelor, in animal and human experimental models. These suggest that antagonism of P2Y 12 receptors decreases markers of inflammation with some evidence that this reduces incidence of adverse clinical sequelae during inflammatory conditions. Interpretation is complicated by pleiotropic effects such as those of the thienopyridines on circulating leucocyte numbers and of ticagrelor on adenosine reuptake. The available evidence suggests that P2Y 12 receptors are prominent mediators of inflammation and P2Y 12 receptor antagonism as a potentially powerful strategy in a broad range of inflammatory conditions. LINKED ARTICLES This article is part of a themed issue on Platelet purinergic receptor and non‐thrombotic disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.4/issuetoc

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAnimalsHumansTicagrelorBlood PlateletsInflammationPlatelet AggregationPrasugrel HydrochlorideThienopyridinesReceptors, Purinergic P2Y12

Stichwörter der Autor:innen

P2Y12 receptorsinflammationleucocytesplatelets

Substanzen

TicagrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsPrasugrel HydrochlorideThienopyridinesReceptors, Purinergic P2Y12

Autor:innen und Institutionen

  • Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
  • NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

ORCID-Profile: William A E Parker, Robert F Storey

Förderung

  • British Heart Foundation

Zitieren

APA

Parker, W. A. E., & Storey, R. F. (2024). The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology, 181(4), 515-531. https://doi.org/10.1111/bph.16256

Vancouver

Parker WAE, Storey RF. The role of platelet P2Y 12 receptors in inflammation. British Journal of Pharmacology. 2024;181(4):515-531. doi:10.1111/bph.16256

BibTeX
@article{Parker2024,
  author = {Parker, William A E and Storey, Robert F},
  title = {The role of platelet P2Y 12 receptors in inflammation},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {4},
  pages = {515--531},
  doi = {10.1111/bph.16256}
}
Kostenlos starten →